Evidence map›Paper›PMID 42642361›Full record

ArticleSignal transduction and targeted therapy2026

Reprogramming translation for rare disease therapy: challenges posed by large genes.

Bikash R Pattnaik, Jose A Sahel

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Bikash R PattnaikDepartment of Pediatrics, University of Wisconsin-Madison, Madison, WI, USA.
Jose A SahelDepartment of Ophthalmology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. sahelja@upmc.edu.ORCID http://orcid.org/0000-0002-4831-1153

Funding

The CRISPR Vision Program: Nonviral Genome Editing Platforms to Treat Inherited Retinal Channelopathies Epqt SupplementU19NS132296 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI Krishanu Saha · 2023 to 2026
$36.8M
Restoring Vision with High-Fidelity Nonsense Codon CorrectionR24EY032434 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI AHERN, CHRISTOPHER A, GAMM, DAVID M · 2021 to 2025
$7.8M
Retinal-adhesive thermoresponsive gel for AAV-mediated gene delivery to the outer retinaR01EY033049 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BELTRAN, WILLIAM A., BYRNE, LEAH · 2022 to 2025
$2.7M
Molecular Therapies for Lebers Congenital Amaurosis Caused by KCNJ13 MutationsR01EY024995 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI PATTNAIK, BIKASH RANJAN · 2015 to 2018
$1.5M
NEI NIH HHS R01 EY024995NEI NIH HHS R01 EY033049NEI NIH HHS R24 EY032434NINDS NIH HHS U19 NS132296
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42642361
PMCPMC13507103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.